CN102300866B - 作为放射性药物的含氮大环共轭物 - Google Patents

作为放射性药物的含氮大环共轭物 Download PDF

Info

Publication number
CN102300866B
CN102300866B CN200980156413.6A CN200980156413A CN102300866B CN 102300866 B CN102300866 B CN 102300866B CN 200980156413 A CN200980156413 A CN 200980156413A CN 102300866 B CN102300866 B CN 102300866B
Authority
CN
China
Prior art keywords
group
certain embodiments
molecular recognition
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980156413.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102300866A (zh
Inventor
史蒂芬·保罗·唐纳利
特雷西·米歇尔·马
伯纳德·丹尼斯·斯甘龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transparent Medicine Co ltd
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008906239A external-priority patent/AU2008906239A0/en
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of CN102300866A publication Critical patent/CN102300866A/zh
Application granted granted Critical
Publication of CN102300866B publication Critical patent/CN102300866B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN200980156413.6A 2008-12-02 2009-12-02 作为放射性药物的含氮大环共轭物 Active CN102300866B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008906239 2008-12-02
AU2008906239A AU2008906239A0 (en) 2008-12-02 Radiopharmaceuticals
PCT/AU2009/001572 WO2010063069A1 (en) 2008-12-02 2009-12-02 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals

Publications (2)

Publication Number Publication Date
CN102300866A CN102300866A (zh) 2011-12-28
CN102300866B true CN102300866B (zh) 2015-08-26

Family

ID=42232814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980156413.6A Active CN102300866B (zh) 2008-12-02 2009-12-02 作为放射性药物的含氮大环共轭物

Country Status (9)

Country Link
US (7) US9701694B2 (https=)
EP (2) EP3098225B1 (https=)
JP (2) JP2012510477A (https=)
CN (1) CN102300866B (https=)
AU (1) AU2009322081C1 (https=)
CA (1) CA2745495C (https=)
DK (1) DK3098225T3 (https=)
ES (1) ES2712881T3 (https=)
WO (1) WO2010063069A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003912A1 (en) * 2011-07-07 2013-01-10 Australian Nuclear Science And Technology Organisation Cryptate compounds
JP6051227B2 (ja) * 2011-12-06 2016-12-27 ザ ユニバーシティ オブ メルボルン 金属放射性医薬品のためのケージアミン配位子の官能化
JP6047581B2 (ja) * 2011-12-06 2016-12-21 ザ ユニバーシティ オブ メルボルン 金属放射性医薬品のためのケージアミン配位子
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
AU2017354941B2 (en) * 2016-11-04 2021-02-11 Clarity Pharmaceuticals Ltd Formulations for radiotherapy and diagnostic imaging
CN115322244B (zh) * 2017-06-06 2025-10-28 透明医药有限公司 放射性药物、放射成像剂及其用途
WO2019195890A1 (en) * 2018-04-11 2019-10-17 Clarity Pharmaceuticals Pty Ltd Formulations and kits for radiotherapy and diagnostic imaging
CN111989324A (zh) 2018-04-11 2020-11-24 墨尔本大学 靶向化合物及其生产方法
US20220313600A1 (en) * 2019-05-24 2022-10-06 Clarity Pharmaceuticals Limited Formulations of psma imaging agents
CN115175910A (zh) * 2019-11-08 2022-10-11 昆士兰大学 放射性标记的靶向配体
CN115003684A (zh) * 2020-01-26 2022-09-02 主线生物科学有限公司 同位素标记的选择性cxcr4结合肽偶联物及其制备和使用方法
MX2022013783A (es) * 2020-05-06 2023-04-19 Univ Cornell Compuestos tratanosticos que contienen cobre y metodos de uso.
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
AU2023322240A1 (en) * 2022-08-11 2025-02-20 Clarity Pharmaceuticals Limited Dimeric radiopharmaceuticals, compositions thereof and uses thereof
CN116589508A (zh) * 2023-05-16 2023-08-15 洛阳师范学院 一种基于半夹心铑构筑单元的矩形分子大环化合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044095A (zh) * 1988-06-24 1990-07-25 唐化学原料公司 大环双官能螯合剂、其配合物和它们的抗体共轭物
WO1995031202A1 (en) * 1994-05-17 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Cage compounds, processes for their preparation and their use as antiviral agents
CN1152880A (zh) * 1994-04-22 1997-06-25 孟山都公司 使用含氮大环配拉体的金属络合物的诊断图像分析的方法
WO2003063912A1 (en) * 2002-01-29 2003-08-07 Bracco Imaging S.P.A. Responsive paramagnetic mri contrast agents
WO2005037862A1 (en) * 2003-10-17 2005-04-28 Ctt Cancer Targeting Technologies Oy Targeting compositions and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001719A1 (en) 1977-10-26 1979-05-02 The Australian National University Metal complexes, their preparation and production of hydrogen peroxide therewith
US5245055A (en) * 1990-12-18 1993-09-14 E. R. Squibb & Sons, Inc. Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol
JPH04244085A (ja) 1990-12-21 1992-09-01 Doujin Kagaku Kenkyusho:Kk 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ
AUPP803899A0 (en) * 1999-01-05 1999-01-28 Australian National University, The Cryptate compounds and methods for diagnosis and therapy.
US6107326A (en) * 1999-04-12 2000-08-22 Cytopharm, Inc. Porphycenes for treatment of microbial populations
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
US9056129B2 (en) * 2007-02-09 2015-06-16 Northeastern University Precision-guided nanoparticle systems for drug delivery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044095A (zh) * 1988-06-24 1990-07-25 唐化学原料公司 大环双官能螯合剂、其配合物和它们的抗体共轭物
CN1152880A (zh) * 1994-04-22 1997-06-25 孟山都公司 使用含氮大环配拉体的金属络合物的诊断图像分析的方法
WO1995031202A1 (en) * 1994-05-17 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Cage compounds, processes for their preparation and their use as antiviral agents
WO2003063912A1 (en) * 2002-01-29 2003-08-07 Bracco Imaging S.P.A. Responsive paramagnetic mri contrast agents
WO2005037862A1 (en) * 2003-10-17 2005-04-28 Ctt Cancer Targeting Technologies Oy Targeting compositions and preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Functional Cage-Amine Complexes: Polymerisable Metallomonomers and Multi-Cage Complexes;Nigel A. Lengkeek;《PhD Thesis-University of Western Australia》;20071231;第200-201页Figure5.1、Figure5.2及Scheme 5.3，第202页5.3.1.1节及Scheme 5.4，第215-216页 *

Also Published As

Publication number Publication date
US9701694B2 (en) 2017-07-11
US12565506B2 (en) 2026-03-03
CN102300866A (zh) 2011-12-28
EP3098225B1 (en) 2018-11-28
US10301326B2 (en) 2019-05-28
EP2370447A4 (en) 2013-08-14
US10870664B2 (en) 2020-12-22
WO2010063069A1 (en) 2010-06-10
AU2009322081C1 (en) 2016-09-01
US11111254B2 (en) 2021-09-07
US20110293517A1 (en) 2011-12-01
US20170267699A1 (en) 2017-09-21
US20190225625A1 (en) 2019-07-25
CA2745495A1 (en) 2010-06-10
AU2009322081B2 (en) 2016-05-26
JP5981580B2 (ja) 2016-08-31
JP2012510477A (ja) 2012-05-10
US20210363161A1 (en) 2021-11-25
US20170267698A1 (en) 2017-09-21
US20240190897A1 (en) 2024-06-13
DK3098225T3 (en) 2019-03-25
CA2745495C (en) 2017-07-18
US20200115391A1 (en) 2020-04-16
EP3098225A1 (en) 2016-11-30
US10544164B2 (en) 2020-01-28
US11905301B2 (en) 2024-02-20
AU2009322081A1 (en) 2011-07-21
ES2712881T3 (es) 2019-05-16
JP2015145367A (ja) 2015-08-13
EP2370447A1 (en) 2011-10-05
EP2370447B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
CN102300866B (zh) 作为放射性药物的含氮大环共轭物
JP6047581B2 (ja) 金属放射性医薬品のためのケージアミン配位子
US9364570B2 (en) Functionalisation of cage amine ligands for metallo-radiopharmaceuticals
HK40080888A (en) Cage amine ligands for metallo-radiopharmaceuticals

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210621

Address after: Cornwallis street, Evely, NSW, Australia 2015

Patentee after: Transparent Medicine Co.,Ltd.

Address before: Melbourne, Australia

Patentee before: THE University OF MELBOURNE

TR01 Transfer of patent right
CP02 Change in the address of a patent holder

Address after: 4 Cornwallis street, Evelyn, NSW, Australia 2015

Patentee after: Transparent Medicine Co.,Ltd.

Address before: Cornwallis street, Evely, NSW, Australia 2015

Patentee before: Transparent Medicine Co.,Ltd.

CP02 Change in the address of a patent holder